Levamisole in Crohn's disease

A randomized, double-blind, placebo-controlled clinical trial

D. B. Sachar, K. P. Rubin, V. Gumaste

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

To evaluate the efficacy of levamisole in the treatment of Crohn's disease, 19 patients were entered into a long-term, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients (eight in the levamisole group and nine in the placebo group) completed the initial treatment arm of the study. Assessments made at 4- and 12-month intervals failed to show any statistically significant difference between the two groups. Sixteen patients embarked on the second segment of the study; six were continued on the same initial therapy while the remaining 10 were crossed over to the alternate treatment. Again, analysis of the clinical scores did not reveal any beneficial effect of levamisole; in fact, all three patients who remained on levamisole for a period of 12 months after cross-over showed deterioration. The overall dismal results have provided no basis for enthusiasm for levamisole in the treatment of Crohn's disease.

Original languageEnglish (US)
Pages (from-to)536-539
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume82
Issue number6
StatePublished - 1987
Externally publishedYes

Fingerprint

Levamisole
Controlled Clinical Trials
Crohn Disease
Placebos
Therapeutics

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Levamisole in Crohn's disease : A randomized, double-blind, placebo-controlled clinical trial. / Sachar, D. B.; Rubin, K. P.; Gumaste, V.

In: American Journal of Gastroenterology, Vol. 82, No. 6, 1987, p. 536-539.

Research output: Contribution to journalArticle

Sachar, D. B. ; Rubin, K. P. ; Gumaste, V. / Levamisole in Crohn's disease : A randomized, double-blind, placebo-controlled clinical trial. In: American Journal of Gastroenterology. 1987 ; Vol. 82, No. 6. pp. 536-539.
@article{aa7724f7c1684679ab1423669d472d41,
title = "Levamisole in Crohn's disease: A randomized, double-blind, placebo-controlled clinical trial",
abstract = "To evaluate the efficacy of levamisole in the treatment of Crohn's disease, 19 patients were entered into a long-term, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients (eight in the levamisole group and nine in the placebo group) completed the initial treatment arm of the study. Assessments made at 4- and 12-month intervals failed to show any statistically significant difference between the two groups. Sixteen patients embarked on the second segment of the study; six were continued on the same initial therapy while the remaining 10 were crossed over to the alternate treatment. Again, analysis of the clinical scores did not reveal any beneficial effect of levamisole; in fact, all three patients who remained on levamisole for a period of 12 months after cross-over showed deterioration. The overall dismal results have provided no basis for enthusiasm for levamisole in the treatment of Crohn's disease.",
author = "Sachar, {D. B.} and Rubin, {K. P.} and V. Gumaste",
year = "1987",
language = "English (US)",
volume = "82",
pages = "536--539",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Levamisole in Crohn's disease

T2 - A randomized, double-blind, placebo-controlled clinical trial

AU - Sachar, D. B.

AU - Rubin, K. P.

AU - Gumaste, V.

PY - 1987

Y1 - 1987

N2 - To evaluate the efficacy of levamisole in the treatment of Crohn's disease, 19 patients were entered into a long-term, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients (eight in the levamisole group and nine in the placebo group) completed the initial treatment arm of the study. Assessments made at 4- and 12-month intervals failed to show any statistically significant difference between the two groups. Sixteen patients embarked on the second segment of the study; six were continued on the same initial therapy while the remaining 10 were crossed over to the alternate treatment. Again, analysis of the clinical scores did not reveal any beneficial effect of levamisole; in fact, all three patients who remained on levamisole for a period of 12 months after cross-over showed deterioration. The overall dismal results have provided no basis for enthusiasm for levamisole in the treatment of Crohn's disease.

AB - To evaluate the efficacy of levamisole in the treatment of Crohn's disease, 19 patients were entered into a long-term, randomized, double-blind, placebo-controlled clinical trial. Seventeen patients (eight in the levamisole group and nine in the placebo group) completed the initial treatment arm of the study. Assessments made at 4- and 12-month intervals failed to show any statistically significant difference between the two groups. Sixteen patients embarked on the second segment of the study; six were continued on the same initial therapy while the remaining 10 were crossed over to the alternate treatment. Again, analysis of the clinical scores did not reveal any beneficial effect of levamisole; in fact, all three patients who remained on levamisole for a period of 12 months after cross-over showed deterioration. The overall dismal results have provided no basis for enthusiasm for levamisole in the treatment of Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=0023194882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023194882&partnerID=8YFLogxK

M3 - Article

VL - 82

SP - 536

EP - 539

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 6

ER -